Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), CUPISCO, Gemcitabine + cisplatin, Paclitaxel / nab-paclitaxel.
Shares Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling, HER2.
Shares Gemcitabine + cisplatin, Platinum agents, HER2, PD-1.
Shares Tumour mutational burden (TMB), Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Nivolumab.
Shares Tumour mutational burden (TMB), Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1.
Shares Tumour mutational burden (TMB), Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Histopathology & immunohistochemistry.
Shares Cancer of unknown primary, favourable subsets, Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Tumour mutational burden (TMB), Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1.
The same record for scripts and assistants; checked 2026-09-08. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.